Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans
Eagle's Eye View: Your Weekly CV Update From ACC.org
Release Date: 04/15/2026
Pulsed Field Ablation and PAS; TRIDENT & Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD). He then explores a report highlighting nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation. Finally, Dr. Eagle presents a summary of the TRIDENT trial, which compares a triple‑pill antihypertensive strategy with conventional...
info_outline
Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patients with noncardioembolic stroke...
info_outline
Early Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle examines early surgery for asymptomatic patients with severe aortic stenosis. He then reviews evidence linking blood pressure trajectories and rapid control to significantly improved outcomes. Finally, he compares percutaneous coronary intervention with medical therapy for chronic total occlusion in patients with chronic coronary disease.
info_outline
Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. He then analyzes the new Joint Clinical Statement focusing on Masters athletes with abnormal cardiovascular findings, followed by details on a study of how participation in the BALANCE Model will impact Medicare spending on semaglutide. Finally, Dr....
info_outline
Top Takeaways from ACC.26
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30. Important studies discussed include: CHAMPION-AF: Left atrial appendage closure vs. anticoagulation for AFib VESALIUS-CV: Evolocumab reduces CV risk in diabetic patients without ASCVD Ez-PAVE: Hitting lower LDL-C target reduces major CV events PRO-TAVI:...
info_outline
New ACC/AHA Dyslipidemia Guidelines Released
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA’s newly released clinical guidelines for managing dyslipidemia.
info_outline
Beta-Blocker vs. Calcium-Channel Blocker in HCM
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion...
info_outline
Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation (PVI)...
info_outline
Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at findings from the in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release...
info_outline
ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF
Eagle's Eye View: Your Weekly CV Update From ACC.org
In this week’s View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels...
info_outlineIn this week’s View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. He then analyzes the new Joint Clinical Statement focusing on Masters athletes with abnormal cardiovascular findings, followed by details on a study of how participation in the BALANCE Model will impact Medicare spending on semaglutide. Finally, Dr. Eagle discusses how modifiable barriers may improve access to quadruple guideline-directed medical therapy for veterans with heart failure with reduced ejection fraction.